| 摘要 |
There is provided novel 4-fluoro-phenyl-methoxy-benzene carboxylic acid compounds (insert formula I) capable of modulating the G-protein-coupled receptor GPR120, which can be used for controlling insulin levels in vivo and for the treatment of conditions such as type II diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels. Also claimed are the compounds for use in the treatment of obesity, type II diabetes and metabolic syndrome. |
